20324 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
METHODS AND COMPOUNDS FOR MODULATING INFLAMMATORY PROCESSES
#302Use of IL-1 antagonists to treat gout
#303Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
#3043'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
#3053′-[(2Z)-[1-(3,4-dimethylphenyl)-1 ,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
#3063′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene] hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
#3073′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
#3083′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
#309Methods for Treating Degenerative Diseases/Injuries
#310Methods For Treating Degenerative Diseases/Injuries
#3113′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
#3124-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
#313SPHERICAL ELEMENTARY GRANULE AND METHOD FOR PRODUCTION THEREOF
#314METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES
#315Treatment for Cardiovascular Disease
#316Use of IL-1 antagonists to treat gout
#317PHARMACEUTICAL COMBINATION
#318Compositions and methods for treating amyloidosis
#319Novel Pharmaceutical
#320Topical Compositions
#321Pyrazolidinol compounds
#322Orally Disintegrating Tablet
#3233,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
#324Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
#325Method of Tonic Treatment With Oxyphenbutazone Derivatives
#326Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
#327Methods and compounds for inhibiting amyloid deposits
#328Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders
#3293,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
#330Shp-2 inhibitors and pharmaceutical compositions comprising them
#3314-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
#332Combination Therapy for Treating Cyclooxygenase-2 Mediated Diseases or Conditions in Patients at Risk of Thrombotic Cardiovascular Events
#333Pharmaceutical combinations for the treatment of head-aches and migraine attacks as well as blisters and packs that contain them
#334MIXTURE FOR TRANSDERMAL DELIVERY OF LOW AND HIGH MOLECULAR WEIGHT COMPOUNDS
#335Method for treating proliferative disorders with HSP90 inhibitors
#336Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators
#337Pyrazolone compounds useful for treatment of cerebrovascular disorders associated with ischemic stroke
#338Synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (BPU) sulfur analogs
#339Treatment for Cardiovascular Disease
#340Pyrazole compounds and uses thereof
#341HETEROCYCLIC MODULATORS OF PPAR
#342Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
#343Inhibitor of cancer bone metastasis
#344COMBINATION
#345Percutaneous absorption type cerebral protective agent
#346Combination comprising a P-gp inhibitor and an anti-epileptic drug
#347Methods for treating degenerative diseases/injuries
#348RYANODINE RECEPTOR BLOCKERS FOR TREATING PAIN
#349Pyrazolidinedione derivatives
#350Pyrazolidinol compounds
#351Treatment of inflammatory conditions
#352Beta-sheet mimetics and methods relating to the use thereof
#353Sodium channel modulators
#354β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
#355Agent for therapeutic treatment of optic nerve diseases and the like
#3563,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
#357Mixture for transdermal delivery of low and high molecular weight compounds
#358Mixture for transdermal delivery of low and high molecular weight compounds
#3593′-[(2z)-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hy-drazino]-2′-hydroxy-[1,1′-piphenyl]-acid bis-(monoethanolamine)
#360Preventive and/or therapeutic drugs for inflammatory intestinal diseases
#361Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions
#362Blood-brain barrier disruption inhibitor
#363Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
#364Use of estrogen related receptor-modulating aryl ethers
#365Percutaneous absorption preparation containing 3-methyl-1-phenyl-2-pyrazolin-5-one
#366Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
#367Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
#368Sodium channel modulators
#369Mixture for transdermal delivery of low and high molecular weight compounds